Latest & greatest articles for thyroid

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on thyroid or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on thyroid and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for thyroid

221. Thyroid hormones for acute kidney injury. (Abstract)

Thyroid hormones for acute kidney injury. Acute kidney injury (AKI), which is common in hospitalised patients, is associated with significant morbidity and mortality. Despite recent advances in treatment, AKI outcomes have not changed substantially during the past four decades, and incidence is increasing. There is an urgent need to explore novel therapeutic agents and revisit some older drugs to review their roles in the management of AKI. Although thyroid hormone therapy has shown promise (...) in experimental animal studies, clinical efficacy and safety have not been systematically assessed for the management of people with AKI.To evaluate the benefits and harms of thyroid hormones for the treatment of hospitalised adults with AKI of any aetiology.We searched the Cochrane Renal Group's Specialised Register, CENTRAL, MEDLINE, and EMBASE. We also checked the reference lists of retrieved studies and articles.Date of search: November 2012Randomised controlled trials (RCTs) and quasi-RCTs (in which

2013 Cochrane

222. Improving Voice Outcomes After Thyroid Surgery

Improving Voice Outcomes After Thyroid Surgery Clinical Practice Guideline: Improving Voice Outcomes after Thyroid Surgery - Sujana S. Chandrasekhar, Gregory W. Randolph, Michael D. Seidman, Richard M. Rosenfeld, Peter Angelos, Julie Barkmeier-Kraemer, Michael S. Benninger, Joel H. Blumin, Gregory Dennis, John Hanks, Megan R. Haymart, Richard T. Kloos, Brenda Seals, Jerry M. Schreibstein, Mack A. Thomas, Carolyn Waddington, Barbara Warren, Peter J. Robertson, 2013 MENU IN THIS JOURNAL Sign (...) and accept the terms and conditions Share URL copied to clipboard View permissions information for this article Clinical Practice Guideline: Improving Voice Outcomes after Thyroid Surgery .entryAuthor" data-author-container-selector=".NLM_contrib-group"> Show all authors , MD 1 1New York Otology, New York, New York, USA by this author for this author , , MD 2 2Department of Otolaryngology, Massachusetts Eye and Ear Infirmary, Boston, Massachusetts, USA by this author for this author , , MD 3 3Department

2013 American Academy of Otolaryngology - Head and Neck Surgery

223. Thyroid Carcinoma

Thyroid Carcinoma Date of origin: 2013 ACR Appropriateness Criteria ® 1 Thyroid Carcinoma American College of Radiology ACR Appropriateness Criteria ® THYROID CARCINOMA Expert Panel on Radiation Oncology–Head & Neck Cancer: Joseph K. Salama, MD 1 ; Daniel W. Golden, MD 2 ; Jonathan J. Beitler, MD, MBA 3 ; Sue S. Yom, MD, PhD 4 ; Madhur Kumar Garg, MD 5 ; Joshua Lawson, MD 6 ; Mark W. McDonald, MD 7 ; Harry Quon, MD, MS 8 ; John A. Ridge, MD, PhD 9 ; Nabil Saba, MD 10 ; Richard V. Smith, MD 11 (...) ; Francis Worden, MD 12 ; Anamaria Reyna Yeung, MD. 13 Summary of Literature Review Introduction/Background Thyroid cancer is the most common endocrine malignancy in the United States, where the annual incidence is approximately 37,000 and increasing due to the more frequent diagnosis of early well-differentiated thyroid carcinoma (WDTC) [1]. Annually, approximately 1,600 people die from thyroid malignancies [2]. Women represent approximately 75% of newly diagnosed thyroid carcinoma cases. Risk factors

2013 American College of Radiology

224. AIUM Practice Parameter for the Performance of a Thyroid and Parathyroid Ultrasound Examination

AIUM Practice Parameter for the Performance of a Thyroid and Parathyroid Ultrasound Examination PRACTICEGUIDELINES AIUM–ACR–SPR–SRU Practice Parameter for the Performance and Interpretation of a Diagnostic Ultrasound Examination of the Extracranial Head and Neck Preamble T he American Institute of Ultrasound in Medicine (AIUM) is a multidisciplinary association dedicated to advancing the safe and effective use of ultrasound in medicine through professional and public education, research (...) ; and Quality Control and Improvement, Safety, doi:10.1002/jum.14830 ©2018 bytheAmericanInstituteof Ultrasound inMedicine | J UltrasoundMed 2018; 9999:1–7 | 0278-4297 | www.aium.orgInfection Control, and Patient Education vary among the organizationsand are addressed byeachseparately. This practice parameter is intended to assist prac- titioners performing ultrasound evaluations of the extracranial head and neck, including evaluation of the thyroid gland, parathyroid glands, parotid glands, submandibular

2013 American Institute of Ultrasound in Medicine

225. Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer Full Text available with Trip Pro

Absolute Risk Prediction of Second Primary Thyroid Cancer Among 5-Year Survivors of Childhood Cancer We developed three absolute risk models for second primary thyroid cancer to assist with long-term clinical monitoring of childhood cancer survivors.We used data from the Childhood Cancer Survivor Study (CCSS) and two nested case-control studies (Nordic CCSS; Late Effects Study Group). Model M1 included self-reported risk factors, model M2 added basic radiation and chemotherapy treatment (...) information abstracted from medical records, and model M3 refined M2 by incorporating reconstructed radiation absorbed dose to the thyroid. All models were validated in an independent cohort of French childhood cancer survivors.M1 included birth year, initial cancer type, age at diagnosis, sex, and past thyroid nodule diagnosis. M2 added radiation (yes/no), radiation to the neck (yes/no), and alkylating agent (yes/no). Past thyroid nodule was consistently the strongest risk factor (M1 relative risk [RR

2012 EvidenceUpdates

226. The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. Full Text available with Trip Pro

The spectrum of thyroid disease and risk of new onset atrial fibrillation: a large population cohort study. To examine the risk of atrial fibrillation in relation to the whole spectrum of thyroid function in a large cohort of patients.Population based cohort study of general practice patients identified by linkage of nationwide registries at the individual level.Primary care patients in the city of Copenhagen.Registry data for 586,460 adults who had their thyroid function evaluated (...) for the first time by their general practitioner during 2000-10 and who were without previously recorded thyroid disease or atrial fibrillation.Poisson regression models used to estimate risk of atrial fibrillation by thyroid function.Of the 586,460 individuals in the study population (mean (SD) age 50.2 (16.9) years, 39% men), 562,461 (96.0%) were euthyroid, 1670 (0.3%) had overt hypothyroidism, 12,087 (2.0%) had subclinical hypothyroidism, 3966 (0.7%) had overt hyperthyroidism, and 6276 (1.0%) had

2012 BMJ

228. Thyroid nodules with indeterminate cytology. Full Text available with Trip Pro

Thyroid nodules with indeterminate cytology. 23150966 2012 11 27 2018 12 02 1533-4406 367 20 2012 11 15 The New England journal of medicine N. Engl. J. Med. Thyroid nodules with indeterminate cytology. 1957; author reply 1958-9 10.1056/NEJMc1211421 Wiseman Sam S Walker Blair B eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2012 Aug 23;367(8):705-15 22731672 Female Gene Expression Gene Expression Profiling methods Humans Male Thyroid Gland pathology Thyroid

2012 NEJM

229. Thyroid nodules with indeterminate cytology. Full Text available with Trip Pro

Thyroid nodules with indeterminate cytology. 23150967 2012 11 27 2018 12 02 1533-4406 367 20 2012 11 15 The New England journal of medicine N. Engl. J. Med. Thyroid nodules with indeterminate cytology. 1957-8; author reply 1958-9 10.1056/NEJMc1211421 Pusztaszeri Marc M eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2012 Aug 23;367(8):765-7 22731671 N Engl J Med. 2012 Aug 23;367(8):705-15 22731672 Female Gene Expression Gene Expression Profiling methods (...) Humans Male Thyroid Gland pathology Thyroid Nodule diagnosis genetics 2012 11 16 6 0 2012 11 16 6 0 2012 12 10 6 0 ppublish 23150967 10.1056/NEJMc1211421 10.1056/NEJMc1211421#SA2

2012 NEJM

230. Thyroid nodules with indeterminate cytology. Full Text available with Trip Pro

Thyroid nodules with indeterminate cytology. 23150968 2012 11 27 2018 12 02 1533-4406 367 20 2012 11 15 The New England journal of medicine N. Engl. J. Med. Thyroid nodules with indeterminate cytology. 1958; author reply 1958-9 10.1056/NEJMc1211421 Domínguez José M JM eng Letter Comment United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2012 Aug 23;367(8):705-15 22731672 Female Gene Expression Gene Expression Profiling methods Humans Male Thyroid Gland pathology Thyroid Nodule

2012 NEJM

231. [Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland]

[Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland] Radiofrequenzablation bei benignen und malignen ver nderungen endokriner organe (schilddr se und nebenniere) [Radiofrequency ablation for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland] Radiofrequenzablation bei benignen und malignen ver nderungen endokriner organe (schilddr se und nebenniere) [Radiofrequency ablation (...) for the treatment of benign and malign nodules of endocrine organs (thyroid gland and adrenal gland] Fischer S, Zechmeister-Koss I Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Fischer S, Zechmeister-Koss I. Radiofrequenzablation bei benignen und malignen ver nderungen endokriner organe (schilddr se und nebenniere). [Radiofrequency ablation

2012 Health Technology Assessment (HTA) Database.

232. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial (Abstract)

Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial No effective standard treatment exists for patients with radioiodine-refractory, advanced differentiated thyroid carcinoma. We aimed to assess efficacy and safety of vandetanib, a tyrosine kinase inhibitor of RET, VEGFR and EGFR signalling, in this setting.In this randomised, double-blind, phase 2 trial, we enrolled adults (aged ≥18 years) with locally advanced or metastatic (...) differentiated thyroid carcinoma (papillary, follicular, or poorly differentiated) at 16 European medical centres. Eligible patients were sequentially randomised in a 1:1 ratio with a standard computerised scheme to receive either vandetanib 300 mg per day (vandetanib group) or matched placebo (placebo group), balanced by centre. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population based on investigator assessment. This study is registered with ClinicalTrials.gov

2012 EvidenceUpdates Controlled trial quality: predicted high

233. Cabozantinib for medullary thyroid cancer

Cabozantinib for medullary thyroid cancer Cabozantinib for medullary thyroid cancer Cabozantinib for medullary thyroid cancer NHSC Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation NHSC. Cabozantinib for medullary thyroid cancer. Birmingham: National Horizon Scanning Centre (NHSC). Horizon Scanning Review. 2012 Final publication URL (...) Indexing Status Subject indexing assigned by CRD MeSH Angiogenesis Inhibitorss; Anilides; Antineoplastic Agents; Thyroid Neoplasms Language Published English Country of organisation England English summary An English language summary is available. Address for correspondence The NIHR Horizon Scanning Centre, Department of Public Health, Epidemiology, and Biostatistics, School of Health and Population Sciences, University of Birmingham, 90 Vincent Drive, Edgbaston, Birmingham, B15 2SP. United Kingdom

2012 Health Technology Assessment (HTA) Database.

234. Minimizing Unnecessary Surgery for Thyroid Nodules. Full Text available with Trip Pro

Minimizing Unnecessary Surgery for Thyroid Nodules. 22731671 2012 08 30 2018 12 01 1533-4406 367 8 2012 Aug 23 The New England journal of medicine N. Engl. J. Med. Minimizing unnecessary surgery for thyroid nodules. 765-7 10.1056/NEJMe1205893 Jameson J Larry JL eng Editorial Comment 2012 06 25 United States N Engl J Med 0255562 0028-4793 AIM IM N Engl J Med. 2012 Nov 15;367(20):1957-8; author reply 1958-9 23150967 N Engl J Med. 2012 Aug 23;367(8):705-15 22731672 Female Gene Expression Gene (...) Expression Profiling methods Humans Male Thyroid Gland pathology Thyroid Nodule diagnosis genetics 2012 6 27 6 0 2012 6 27 6 0 2012 8 31 6 0 ppublish 22731671 10.1056/NEJMe1205893

2012 NEJM

235. Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. Full Text available with Trip Pro

Preoperative Diagnosis of Benign Thyroid Nodules with Indeterminate Cytology. Approximately 15 to 30% of thyroid nodules evaluated by means of fine-needle aspiration are not clearly benign or malignant. Patients with cytologically indeterminate nodules are often referred for diagnostic surgery, though most of these nodules prove to be benign. A novel diagnostic test that measures the expression of 167 genes has shown promise in improving preoperative risk assessment.We performed a 19-month (...) , prospective, multicenter validation study involving 49 clinical sites, 3789 patients, and 4812 fine-needle aspirates from thyroid nodules 1 cm or larger that required evaluation. We obtained 577 cytologically indeterminate aspirates, 413 of which had corresponding histopathological specimens from excised lesions. Results of a central, blinded histopathological review served as the reference standard. After inclusion criteria were met, a gene-expression classifier was used to test 265 indeterminate nodules

2012 NEJM

236. Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules Full Text available with Trip Pro

Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules Cost-effectiveness of a novel molecular test for cytologically indeterminate thyroid nodules Li H, Robinson KA, Anton B, Saldanha IJ, Ladenson PW Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary (...) of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. CRD summary This study assessed the cost-effectiveness of a novel molecular test to diagnose cytologically indeterminate thyroid nodules for surgery. The authors concluded that the new molecular test was cost saving and more beneficial than the usual analysis of cytology alone. The methods were valid and transparent, and the results were clearly reported

2012 NHS Economic Evaluation Database.

237. Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review

Positron emission tomography and positron emission tomography-CT evaluation for recurrent papillary thyroid carcinoma: meta-analysis and literature review Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2012 DARE.

238. Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study. Full Text available with Trip Pro

Influence of experience on performance of individual surgeons in thyroid surgery: prospective cross sectional multicentre study. To determine the association between surgeons' experience and postoperative complications in thyroid surgery.Prospective cross sectional multicentre study.High volume referral centres in five academic hospitals in France.All patients who underwent a thyroidectomy undertaken by every surgeon in these hospitals from 1 April 2008 to 31 December 2009.Presence of two (...) permanent major complications (recurrent laryngeal nerve palsy or hypoparathyroidism), six months after thyroid surgery. We used mixed effects logistic regression to determine the association between length of experience and postoperative complications.28 surgeons completed 3574 thyroid procedures during a one year period. Overall rates of recurrent laryngeal nerve palsy and hypoparathyroidism were 2.08% (95% confidence interval 1.53% to 2.67%) and 2.69% (2.10% to 3.31%), respectively. In a multivariate

2012 BMJ

239. SNMMI Procedure Standard for Therapy of Thyroid Disease with 131I (Sodium Iodide) 3.0

SNMMI Procedure Standard for Therapy of Thyroid Disease with 131I (Sodium Iodide) 3.0 The SNM Practice Guideline for Therapy of Thyroid Disease with 131 I 3.0* Edward B.Silberstein 1 (Chair),AbassAlavi 2 ,HelenaR.Balon 3 ,SusanE.M.Clarke 4 ,ChaitanyaDivgi 5 ,MichaelJ.Gelfand 6 , StanleyJ.Goldsmith 7 ,HosseinJadvar 8 ,CarolS.Marcus 9 ,William H.Martin 10 ,J.AnthonyParker 11 ,HenryD. Royal 12 , SalilD. Sarkar 13 ,Michael Stabin 14 ,and Alan D. Waxman 15 1 UC Health University Hospital, Cincinnati (...) of personnel (in the United States) 3 VI. Procedure/speci?cations of the examination 4 A. Therapy of Graves disease, toxic nodules, and nontoxic nodular goiter 4 1. Goals 4 2. Patient preparation: thionamides, consent form, rhTSH use 4 3. Information required by the physician performing the procedure; scintigraphy; pregnancy and lactation 5 4. Selection of administered activity 6 5. Therapeutic procedure for administration of 131 I 6 6. Follow-up 6 B. 131 I therapy of thyroid cancer to ablate post

2012 Society of Nuclear Medicine and Molecular Imaging

240. Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer

Diagnostic use of thyrotropin alfa-rch for Patients with Well-Differentiated Thyroid Cancer 1 Public Summary Document Application 1156: The diagnostic use of thyrogen for patients with well-differentiated thyroid cancer Applicant: Genzyme Australasia Date of MSAC consideration: 29 March 2012. 1. Purpose of application In December 2010, the Department of Health and Ageing received an application from Genzyme Australasia, the Australian distributor of the Thyrogen® brand of thyrotropin alfa-rch (...) , requesting an extension of the current Medicare Benefits Schedule (MBS) listing for thyrotropin alfa-rch (recombinant human thyroid stimulating hormone). Recombinant human thyroid-stimulating hormone (thyrotropin alfa-rch) is used as a component of a diagnostic test for recurrence of thyroid cancer. Patients who have had well-differentiated thyroid cancer and who have been successfully treated by surgical removal of the thyroid gland (thyroidectomy), followed by treatment with radioactive iodine, require

2012 Medical Services Advisory Committee